Clinical trials: WHO Grade II Glioma
Recurrent Glioblastoma, Recurrent Malignant Glioma
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is…
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT04214392
- Testing
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- City of Hope Medical Center
WHO Grade II Glioma
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
- Trial name
- NCT04458272
- Testing
- DS-1001b
- Where
- 11 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent).
- Conditions
- Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
- Trial name
- NCT04485559
- Testing
- Everolimus, Trametinib
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Recurrent Glioblastoma, Recurrent Malignant Glioma
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory).
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT02208362
- Testing
- Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, WHO Grade II Glioma
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
This trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers.
- Conditions
- Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
- Trial name
- NCT04479696
- Testing
- Educational Intervention, Questionnaire Administration, Survey Administration
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas.
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype
- Trial name
- NCT04623931
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma.
- Conditions
- Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
- Trial name
- NCT04540107
- Testing
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Susan Chang
Glioblastoma, IDH1 Gene Mutation
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back.
- Conditions
- Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma
- Trial name
- PNOC017 (NCT03749187)
- Testing
- PARP Inhibitor BGB-290, Temozolomide (TMZ)
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Francisco
Intracranial Neoplasm, Low Grade Glioma
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back.
- Conditions
- Intracranial Neoplasm, Low Grade Glioma, Recurrent Glioblastoma, Recurrent World Health Organization (WHO) Grade II Glioma
- Trial name
- UC-GlioFET (NCT04044937)
- Testing
- F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Thomas Hope
Glioblastoma, WHO Grade II Glioma
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma.
- Conditions
- Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
- Trial name
- NCT03251027
- Testing
- Intensity-Modulated Radiation Therapy, Quality-of-Life
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
IDH1 Mutation, IDH2 Mutation
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back.
- Conditions
- IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma
- Trial name
- NCT03914742
- Testing
- PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Solid Tumor, CNS Tumor
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib. The phase 2 study will evaluate efficacy and safety of infigratinib.
- Conditions
- Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
- Trial name
- NEWEL (NCT05222165)
- Testing
- Infigratinib
- Where
- 10 sites in United States, Canada and 1 more
- Sponsor
- Helsinn Healthcare SA
Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma.
- Conditions
- Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas, Oligodendrogliomas, Mixed Oligoastrocytomas
- Trial name
- NCT02023905
- Testing
- Everolimus, Temozolomide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
This is a pilot study of a vaccination regime that is designed to efficiently induce anti-tumor T-cell responses in patients with WHO grade II glioma.
- Trial name
- NCT01678352
- Testing
- Tumor Lysate Vaccine, Imiquimod
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Frank Lieberman